Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

Miyawaki, Shuichi; Hatsumi, Nahoko; Tamaki, Toshiharu; Naoe, Tomoki; Ozawa, Keiya; Kïtamura, Kazuo; Karasuno, Takahiro; Mitani, Kinuko; Kodera, Yoshihisa; Yamagami, Tamotsu; Koga, Daisuke

doi:10.3109/10428194.2010.507829

Cited by 34 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WT1, the gene mutated in Wilms' tumor, was found expressed in acute myeloid leukemia (AML), and the level of its expression was reported to be associated with minimal residual disease of AML after chemotherapy (9,10). Since WT1 level is very high at the time of AML diagnosis, PB is widely used for this purpose, though BM samples usually show about 10 times higher WT1 level than PB samples.…”

Section: Introductionmentioning

confidence: 99%

The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons

et al. 2015

View full text Add to dashboard Cite

Objective Myelodysplastic syndromes (MDS) are a group of hematological neoplasms associated with ineffective hematopoiesis and that transform to acute leukemia. Distinguishing MDS from other cytopenias is sometimes difficult even for trained hematologists. WT1, the gene mutated in Wilms' tumor, was found expressed in acute myeloid leukemia and MDS. The amount of WT1 in peripheral blood and bone marrow (BM) is low in low-risk MDS subtypes, and is high in high-risk MDS subtypes. However, the role of WT1 in the differential diagnosis between MDS and other diseases showing cytopenia has not been fully addressed. The present study evaluated whether WT1 expression level can assist in the differential diagnosis of MDS from other cytopenias. Methods The amount of WT1 message was evaluated among 56 MDS patients and 47 patients with cytopenia for various other reasons (cytopenia VR) at the Nagasaki University Hospital. Results The level of WT1 was significantly related to the percentage of blasts in BM among MDS cases, and the type of French-American-British classification of MDS; refractory anemia (RA) cases showed significantly lower WT1 level than patients with RA with excess blasts. WT1 level was significantly related to the prognostic risk categories of MDS by the International Prognostic Scoring System (IPSS) and the revised IPSS. Although the blast percentage in the BM of RA and cytopenia VR were both less than 5%, there was a significant difference in the level of WT1 between MDS and cytopenia VR. Conclusion WT1 might be a good marker to differentiate low blast percentage MDS and cytopenia VR.

show abstract

Section: Introductionmentioning

confidence: 99%

The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons

et al. 2015

View full text Add to dashboard Cite

show abstract

“…RNA was extracted from leukocytes in the PB and from nucleated cells in the BM using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and WT1 mRNA was measured using a WT1 mRNA Assay Kit (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) [11]. cDNA was synthesized from 1 µg of extracted RNA by reverse transcription using the random hexamer method.…”

Section: Measurement Of Wt1 Mrna Levelsmentioning

confidence: 99%

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

Kobayashi

Ueda

Nannya

et al. 2016

CBM

Self Cite

View full text Add to dashboard Cite

Abstract.BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK-0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and 10 4 copies/µg RNA groups and between the 500-10 4 and 10 4 copies/µg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 10 4 copies/µg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION:The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.

show abstract

“…Wilms' tumor 1 (WT1) is expressed in high frequency in the PB and BM of many patients with acute myeloid leukemia (AML) [20,21]. The development of in vitro WT1 messenger RNA (mRNA) diagnostics has resulted in its wide use in clinical practice as an MRD monitoring marker.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Wt1 mRNA Levels in Japanese Acute Lymphoblastic Leukemia Patients

Hashii¹,

Kosaka²,

Watanabe³

et al. 2017

J Leuk

Self Cite

View full text Add to dashboard Cite

Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

Cited by 34 publications

References 17 publications

The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons

The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

Clinical Significance of Wt1 mRNA Levels in Japanese Acute Lymphoblastic Leukemia Patients

Contact Info

Product

Resources

About